September 2, 2024
Zühlke Group announces the appointment of Angeli Möller, PhD as Group Chief Health Officer and member of the Group Executive Committee (GEX), effective 1 September 2024. Fabrizio Ferrandina, Group CEO at Zühlke, remarked, "We are delighted to welcome Angeli to our Group Executive Committee. Her deep expertise in healthcare and digital transformation will be instrumental as we continue to grow our footprint in the health sector. We are confident that her leadership will greatly benefit our clients, partners, and employees."
As Group Chief Health Officer, Angeli Möller will be responsible for leading and steering Zühlke's health business globally, ensuring the company maximizes its impact on the health industry. Her leadership will focus on setting the strategic direction for the Business Unit Health, fostering relationships with existing and prospective clients, and driving forward Zühlke's mission to transform organizations through innovative solutions.
Commenting on her appointment, Angeli Möller said, "I am excited to join Zühlke Group and to lead its Health business. My passion for leveraging technology to transform healthcare aligns perfectly with the vision of Zühlke. I look forward to working with the team to drive innovation and create a positive impact on people’s lives and the planet."
Before joining Zühlke, Angeli Möller was Managing Director at Sequoia Growth, where she provided strategic consulting and technical guidance to clients across various sectors. Her previous roles include senior positions at Roche and Bayer, such as Head of Data and Integrations at Roche and Vice President of Global Data Assets at Bayer.
In addition to her industry roles, Angeli Möller co-founded The Alliance for Artificial Intelligence in Healthcare, a global advocacy organization that supports the advancement of AI in the healthcare sector. She also contributes her expertise as a scientific advisory board member of Multiomic Health and as a council member of the UK’s Science and Technology Facilities Council.